Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
c(TNYL-RAW)-DOX@HAuNS
- Development stage
- Preclinical
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- Nanoparticles → Drug Delivery Systems, Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
c(TNYL-RAW)-DOX@HAuNS (also known as T-DOX@HAuNS) is a preclinical targeted nanoconstruct designed for combined photothermal therapy and chemotherapy. It consists of hollow gold nanospheres (HAuNS) loaded with the chemotherapeutic agent doxorubicin (DOX) and conjugated via a PEG linker to c(TNYL-RAW), a cyclic 17-mer peptide that acts as an antagonist with high binding affinity for the ephrin type-B receptor 4 (EphB4). The nanoconstruct selectively targets EphB4-overexpressing tumor cells, where near-infrared (NIR) laser irradiation triggers both photothermal ablation and localized release of doxorubicin. Preclinical studies have demonstrated significant antitumor efficacy and reduced systemic toxicity in mouse models of EphB4-positive ovarian and breast cancers.
- Other names
- c(TNYL-RAW)-conjugated DOX@HAuNSDOX@c(TNYL-RAW)-HAuNSdoxorubicin-loaded hollow gold nanospheres conjugated to c(TNYL-RAW)
02
Targets
EPHB4 (Ephrin type-B receptor 4)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on c(TNYL-RAW)-DOX@HAuNS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on c(TNYL-RAW)-DOX@HAuNS.